Evaluation of Genetic Factors for Warfarin Dose Prediction
Open Access
- 1 March 2007
- journal article
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 5 (1) , 8-16
- https://doi.org/10.3121/cmr.2007.724
Abstract
Objectives: Warfarin is a commonly prescribed anticoagulant drug used to prevent thromboses that may arise as a consequence of orthopedic and vascular surgery or underlying cardiovascular disease. Warfarin is associated with a notoriously narrow therapeutic window where small variations in dosing may result in hemorrhagic or thrombotic complications. To ultimately improve dosing of warfarin, we evaluated models for stable maintenance dose that incorporated both clinical and genetic factors.Keywords
This publication has 33 references indexed in Scilit:
- APOE genotype makes a small contribution to warfarin dose requirementsPharmacogenetics and Genomics, 2006
- Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosingBlood, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated?Stroke, 2005
- Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeThrombosis and Haemostasis, 2005
- Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1Thrombosis and Haemostasis, 2005
- The Inhibitory Effect of Calumenin on the Vitamin K-dependent γ-Carboxylation SystemJournal of Biological Chemistry, 2004
- Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivityBlood, 2004
- Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomesXenobiotica, 1998
- The log transformation is specialStatistics in Medicine, 1995